Literature DB >> 1348932

Genomic differences between O6-methylguanine-DNA methyltransferase proficient (Mex+) and deficient (Mex-) cell lines: possible role of genetic and epigenetic changes in conversion of Mex+ into Mex-.

G Fritz1, B Kaina.   

Abstract

Cell lines that possess O6-methylguanine-DNA methyltransferase (MGMT) repair activity (Mex+ phenotype) or are deficient for MGMT (Mex-) are compared at genomic level. It is shown that 1) 208F rat cells do not contain the MGMT gene, as detected by Southern blot hybridization. 2) Mex- HeLa MR and CHO-9 cells express very low amounts of MGMT mRNA, as detected by PCR. The size of the MGMT specific PCR product was slightly smaller than that generated from Mex+ HeLa S3 cells. 3) HeLa MR, compared to various human Mex+ cell lines, shows a restriction fragment length polymorphism indicating mutational alteration of MGMT gene sequences. 4) Mex- cells (HeLa MR) and cells that express very low MGMT activity (GM637) exhibit hypomethylation of the MGMT gene as revealed by MspI/HpaII restriction digests. 5) Exposure of Mex- cells to 5-azacytidine and selection with N-hydroxyethyl-N-chloroethylnitrosourea (HeCNU) did not yield Mex+ revertants. With V79 cells treated with 5-azacytidine clones resistant to HeCNU were isolated. These cells were MGMT deficient and not cross-resistant to N-methyl-N'-nitro-N-nitrosoguanidine indicating the existance of a defence mechanism other than MGMT against chloroethylating agents. The data suggest down-regulation of MGMT transcription accompanied by decreasing CpG methylation, but in some cell lines also mutational alterations to be involved in extinction of the Mex+ phenotype.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1348932     DOI: 10.1016/s0006-291x(05)80315-8

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.

Authors:  Hinke F van Thuijl; Tali Mazor; Brett E Johnson; Shaun D Fouse; Koki Aihara; Chibo Hong; Annika Malmström; Martin Hallbeck; Jan J Heimans; Jenneke J Kloezeman; Marie Stenmark-Askmalm; Martine L M Lamfers; Nobuhito Saito; Hiroyuki Aburatani; Akitake Mukasa; Mitchell S Berger; Peter Söderkvist; Barry S Taylor; Annette M Molinaro; Pieter Wesseling; Jaap C Reijneveld; Susan M Chang; Bauke Ylstra; Joseph F Costello
Journal:  Acta Neuropathol       Date:  2015-02-28       Impact factor: 17.088

2.  The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide.

Authors:  Erika L Moen; Amy L Stark; Wei Zhang; M Eileen Dolan; Lucy A Godley
Journal:  Mol Cancer Ther       Date:  2014-02-25       Impact factor: 6.261

3.  Inactive O6-methylguanine-DNA methyltransferase in human cells.

Authors:  N Zhukovskaya; B Rydberg; P Karran
Journal:  Nucleic Acids Res       Date:  1992-11-25       Impact factor: 16.971

4.  Influence of DNA repair on nonlinear dose-responses for mutation.

Authors:  Adam D Thomas; Gareth J S Jenkins; Bernd Kaina; Owen G Bodger; Karl-Heinz Tomaszowski; Paul D Lewis; Shareen H Doak; George E Johnson
Journal:  Toxicol Sci       Date:  2013-01-03       Impact factor: 4.849

5.  CpG methylation of MGMT and hMLH1 promoter in hepatocellular carcinoma associated with hepatitis viral infection.

Authors:  S Matsukura; H Soejima; T Nakagawachi; H Yakushiji; A Ogawa; M Fukuhara; K Miyazaki; Y Nakabeppu; M Sekiguchi; T Mukai
Journal:  Br J Cancer       Date:  2003-02-24       Impact factor: 7.640

6.  Drugs and Epigenetic Molecular Functions. A Pharmacological Data Scientometric Analysis.

Authors:  Dario Kringel; Sebastian Malkusch; Jörn Lötsch
Journal:  Int J Mol Sci       Date:  2021-07-06       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.